Design Therapeutics is a biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
Aug 08, 2022
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
Aug 03, 2022
Jun 01, 2022